No Data
No Data
Morgan Stanley Maintains Lyell Immunopharma(LYEL.US) With Hold Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Reported Earlier, Lyell Releases IMPT-314 Phase 1-2 Results, Highlighting Efficacy And Manageable Safety In B-Cell Lymphoma Treatment At ASH 2024
Lyell Immunopharma Announces Promising Initial Clinical Data for IMPT-314 in Treatment of CAR T-Naïve Patients With Large B-Cell Lymphoma
Express News | Lyell Immunopharma Inc - Impt-314 Receives Fast Track Designation From FDA
Teddy123 OP : Move won't u